• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

More HCV resignations





























I recommend you focus on your messaging and closing right now. Trust me.

Rep: So Doctor. If your patients have a strong back and a strong stomach they can take VPak. The box only weighs 50lbs and there are only 10 pills a day. Will you prescribe this shitty product for your patients that have HCV? And will you use this free voucher for a patient that needs VPak.

Dr: Oh sorry what was that? You lost me at VPak.
 












I recommend you focus on your messaging and closing right now. Trust me.

I agree with the person who posted the question. It puts doubt in the minds of the doctors bc their peers are the ones leaving. I've had a customer ask me why the turnover rate is high. Puts doubts in their minds too. I would have liked to have known who had left so I wasn't blindsided by my customer.
 
















Hang in there for ~4 months, if you can stomach it! Merck will be going full force in HCV in ~10 months!! The FDA will review grazoprevir/elbagavir (100mg/50mg), an investigational single tablet regimen (STR), for treatment of hepatitis C (HCV) genotypes 1, 4 and 6.
 




















We must find more, more, MORE genotypes to cure... Genotype 9, 12, 15, 69...like lotto numbers... Then we can add more and more pills to the MegaViraVieZilla Pak!! The cashregister rings thoughout the land!!